Sandoz and Biocon announce collaboration for commercialisation of biosimilar medicines

Jan 18, 2018

Sandoz and Biocon announce a collaboration to develop and commercialise multiple biosimilar medicines.  The companies will share responsibility for development, manufacturing and regulatory approvals. Sandoz is responsible for leading commercialisation in the US & EU, while Biocon will lead commercialisation efforts in the rest of the world.

Print Page Mail Article